Elutia Inc. Class A Common Stock (ELUT) Stock Price

ELUTStock

$1.01−54.31%52W

Market Cap$44.73M

P/E0.70x

PEG Ratio—

Div yield—

Beta0.87

ELUT Share Price Chart

Favorite Metrics

Price vs S&P 500 (26W)-31.66%

Price vs S&P 500 (4W)1.32%

VGM Score41.19

P/E Ratio (Annual)0.70x

Book Value / Share (Quarterly)$0.51

P/TBV (Annual)1.13x

Indicated Dividend (Annual)$0.00

Revenue Growth (3Y)-37.01%

Cash Flow / Share (Quarterly)$-1.04

Price vs S&P 500 (YTD)25.85%

Gross Margin (TTM)54.02%

Net Profit Margin (TTM)312.09%

EPS (TTM)$1.16

10-Day Avg Trading Volume0.05M

EPS Excl Extra (TTM)$1.16

Revenue Growth (5Y)-22.04%

EPS (Annual)$1.29

ROI (Annual)192.90%

Gross Margin (Annual)53.66%

Net Profit Margin (5Y Avg)-11.71%

Cash / Share (Quarterly)$0.64

P/E Basic Excl Extra (TTM)0.75x

Revenue Growth QoQ (YoY)-48.36%

P/E Normalized (Annual)0.70x

ROA (Last FY)85.61%

Revenue Growth TTM (YoY)-32.64%

EBITD / Share (TTM)$-0.61

Operating Margin (TTM)-175.27%

Cash Flow / Share (Annual)$-1.09

P/B Ratio1.67x

P/B Ratio (Quarterly)1.99x

Net Income / Employee (Annual)$2,135,200

EV / Revenue (TTM)0.57x

Net Interest Coverage (TTM)-1.87x

ROA (TTM)110.27%

EPS Incl Extra (Annual)$1.29

Current Ratio (Annual)2.22x

Quick Ratio (Quarterly)1.85x

3-Month Avg Trading Volume0.09M

52-Week Price Return-54.31%

P/E Incl Extra (TTM)0.75x

Revenue / Employee (TTM)$638,800

Tangible BV / Share (Quarterly)$0.48

P/S Ratio (Annual)3.05x

Asset Turnover (Annual)0.20x

52-Week High$2.50

Operating Margin (5Y Avg)-115.31%

EPS Excl Extra (Annual)$1.29

CapEx CAGR (5Y)24.00%

26-Week Price Return-20.42%

Quick Ratio (Annual)2.03x

13-Week Price Return-20.42%

Total Debt / Equity (Annual)0.00x

Current Ratio (Quarterly)2.05x

Enterprise Value$9.05M

Revenue / Share Growth (5Y)-41.06%

Asset Turnover (TTM)0.35x

Revenue / Employee (Annual)$491,700

Inventory Turnover (Annual)1.75x

Pretax Margin (Annual)-129.00%

Cash / Share (Annual)$0.85

3-Month Return Std Dev60.74%

Gross Margin (5Y Avg)41.02%

Net Income / Employee (TTM)$1,993,800

ROE (Last FY)192.90%

Net Interest Coverage (Annual)-4.06x

EPS Basic Excl Extra (Annual)$1.29

Receivables Turnover (TTM)6.48x

Total Debt / Equity (Quarterly)0.00x

EPS Incl Extra (TTM)$1.16

Receivables Turnover (Annual)6.13x

ROI (TTM)252.28%

P/S Ratio (TTM)2.35x

Pretax Margin (5Y Avg)-120.13%

Revenue / Share (Annual)$0.30

Tangible BV / Share (Annual)$0.61

Price vs S&P 500 (52W)-72.62%

P/E Ratio (TTM)0.75x

Year-to-Date Return37.81%

5-Day Price Return4.95%

EPS Normalized (Annual)$1.29

ROA (5Y Avg)-47.04%

Net Profit Margin (Annual)434.23%

Month-to-Date Return11.46%

Cash Flow / Share (TTM)$-1.72

EBITD / Share (Annual)$-0.58

Operating Margin (Annual)-218.91%

LT Debt / Equity (Annual)0.00x

P/E Excl Extra (TTM)0.75x

LT Debt / Equity (Quarterly)0.00x

EPS Basic Excl Extra (TTM)$1.16

P/TBV (Quarterly)2.11x

P/B Ratio (Annual)1.07x

Inventory Turnover (TTM)2.12x

Pretax Margin (TTM)-152.29%

Book Value / Share (Annual)$0.65

Price vs S&P 500 (13W)-23.21%

Beta0.87x

Revenue / Share (TTM)$0.37

ROE (TTM)252.28%

52-Week Low$0.50

vGradeA

gGradeF

mGradeD

vgmGradeC

ELUT Earnings Surprise History

Q2 25-0.23est. -0.17

Q3 25-0.09est. -0.15

Q4 251.48est. -0.14

Q1 26-0.17est. -0.15

Q2 26-0.17est. -0.15

ELUT Analyst Recommendations

May 2026

Jun 2026

Jul 2026

Aug 2026

4.14

Industry Peers — Biological Products(183)

Symbol	Value Score	Growth Score	Momentum Score	Price
ELUTElutia Inc. Class A Common Stock	A	F	D	$1.01
AMGNAmgen Inc	C	C	B	$442.24
GILDGilead Sciences Inc	C	B	B	$148.77
MRNAModerna, Inc. Common Stock	D	C	A	$158.83
ARGXargenx SE American Depositary Shares	D	A	B	$1019.49
RVMDRevolution Medicines, Inc. Common Stock	F	—	A	$211.38
BIIBBiogen Inc. Common Stock	C	D	B	$220.77
BNTXBioNTech SE American Depositary Share	C	C	B	$114.05
NBIXNeurocrine Biosciences Inc	C	B	C	$153.37
EXELExelixis Inc	C	B	B	$56.72
HALOHalozyme Therapeutics, Inc.	C	B	A	$109.32
TECHBio-Techne Corp.	D	C	B	$72.33
KRYSKrystal Biotech, Inc. Common Stock	D	B	B	$356.19
KYMRKymera Therapeutics, Inc. Common Stock	D	B	B	$126.64
RGENRepligen Corp	D	C	A	$181.69
APGEApogee Therapeutics, Inc. Common Stock	—	—	A	$134.85
TWSTTwist Bioscience Corporation Common Stock	D	B	A	$151.42
PCVXVaxcyte, Inc. Common Stock	—	—	B	$61.09
QGENQIAGEN N.V.	C	C	C	$43.65
IMVTImmunovant, Inc. Common Stock	—	—	B	$43.50
IBRXImmunityBio, Inc. Common Stock	F	A	C	$8.19
SRRKScholar Rock Holding Corporation Common Stock	F	—	B	$58.25
CGONCG Oncology, Inc. Common stock	F	A	A	$78.95
CRSPCRISPR Therapeutics AG	D	B	B	$60.90
RLAYRelay Therapeutics, Inc. Common Stock	F	D	A	$20.57
ADPTAdaptive Biotechnologies Corporation Common Stock	D	B	A	$26.25
DNLIDenali Therapeutics Inc. Common Stock	F	—	B	$24.93
IOVAIovance Biotherapeutics, Inc. Common Stock	C	B	A	$8.44
BEAMBeam Therapeutics Inc. Common Stock	C	B	B	$31.03
TARSTarsus Pharmaceuticals, Inc. Common Stock	D	A	B	$71.45
BCRXBioCryst Pharmaceuticals Inc	B	A	B	$9.83
KODKodiak Sciences Inc Common Stock	—	—	B	$39.46
COAGHemab Therapeutics Holdings, Inc. Common Stock	—	—	B	$49.65
MESOMesoblast Limited American Depositary Shares	D	B	C	$17.19
VCELVericel Corporation	D	B	C	$43.22
ADMAADMA Biologics, Inc.	C	C	C	$9.72
TSHATaysha Gene Therapies, Inc. Common Stock	F	B	B	$6.20
IMCRImmunocore Holdings plc American Depositary Shares	D	B	B	$37.40
RXRXRecursion Pharmaceuticals, Inc. Class A Common Stock	D	C	C	$3.56
VIRVir Biotechnology, Inc. Common Stock	B	B	B	$10.71
INBXInhibrx Biosciences, Inc. Common Stock	D	C	B	$122.72
ALVOAlvotech Ordinary Shares	C	D	B	$5.05
MAZEMaze Therapeutics, Inc. Common Stock	—	—	B	$30.42
NVAXNovavax Inc	B	D	C	$9.44
REPLReplimune Group, Inc.	—	—	A	$15.80
SLBTSL Science Holding Limited Ordinary Shares	—	—	F	$2.64
MGTXMeiraGTx Holdings plc Ordinary Shares	D	C	A	$14.92
VORVor Biopharma Inc. Common Stock	—	—	B	$24.01
CGEMCullinan Therapeutics, Inc. Common Stock	—	—	A	$22.95
IMTXImmatics N.V. Ordinary Shares	C	D	C	$9.24
ODTXOdyssey Therapeutics, Inc. Common Stock	—	C	A	$26.23

About Elutia Inc. Class A Common Stock

Elutia Inc (formerly Aziyo Biologics Inc) is a commercial-stage regenerative medicine company that develops products to improve surgical outcomes and reduce complications associated with implantable medical devices. The company operates three segments—Device Protection, Women's Health, and Cardiovascular—with Women's Health as its primary revenue driver. Its product portfolio addresses unmet clinical needs including scar tissue formation, implant rejection, capsular contraction, and device-related complications.